Menu
371 estudos publicados.
› Acesso aberto
Imler A, Bulsara C, Bulsara M, Vickery A, Jacques A, Codde J. Examining the use of cannabidiol and delta-9-tetrahydrocannabinol-based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double-blind randomised crossover trial [published online ahead of print, 2023 Jun 15]. Australas J Ageing. 2023;10.1111/ajag.13224. doi:10.1111/ajag.13224
› Acesso aberto
Thanabalasingam SJ, et al. Cannabis and its derivatives for the use of motor symptoms in Parkinson’s disease: a systematic review and meta-analysis. Ther Adv Neurol Disord 2021; 14:17562864211018561
› Acesso aberto
Xiong Y & Lim CS. Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease. Brain Sci. 2021; 11(9):1211
› Acesso pago
Zhang XB, et al. Roles of Cannabidiol in the Treatment and Prevention of Alzheimer’s Disease by Multi-target Actions. Mini Rev Med Chem 2022; 22(1):43-51
› Acesso aberto
Cooray R, et al. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review. Mol Neurobiol 2020.
› Acesso pago
Cristino L, et al. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol 16(1):9-29.
› Acesso aberto
Monteiro KLC, et al. Cannabinoid pharmacology and its therapeutic uses in Alzheimer’s disease. Neural Regen Res. 2021; 16(5):990-991.
› Acesso aberto
Peprah K, McCormack S. Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; . 2019.
› Acesso aberto
Stella F, et al. Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: systematic review. Trends Psychiatry Psychother. 2021.
› Acesso pago
Hasbi A, Madras BK, George SR. Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review. Brain Sci. 2023;13(2):325. Published 2023 Feb 14. doi:10.3390/brainsci13020325
→ Link de acesso
› Acesso pago
Gournay, L.R., Ferretti, M.L., Bilsky, S. et al. The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo controlled trial. Psychopharmacology (2023).
→ Link de acesso
› Acesso aberto
Linares et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test . Braz J Psychiatry. 2019; 41(1):9-14
→ Link de acesso
› Acesso aberto
Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18-041.
→ Link de acesso
› Acesso aberto
Alexander C & Vasefi M. Cannabidiol and the corticoraphe circuit in post-traumatic stress disorder. IBRO Neurosci Rep 2021; 11:88-102
→ Link de acesso
› Acesso aberto
Bolsoni LM, et al. The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event. Braz J Psychiatry 2022; S1516-44462022005004202
→ Link de acesso
› Acesso aberto
Martin EL, et al. Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial. Front Psychiatry. 2021; 12:729800
→ Link de acesso
› Acesso aberto
Dahlgren, Mary Kathryn, et al. “Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial.” Communications Medicine 2.1 (2022)
→ Link de acesso
› Acesso aberto
Zuari A, et al. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol. 2017; 8:259
→ Link de acesso
› Acesso aberto
Aran A, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism. 2021 ;12(1):6.
→ Link de acesso
› Acesso aberto
Fletcher S, et al. Symptoms, adverse events, and outcomes in the use of medicinal cannabis in children and adolescents with autism spectrum disorder: a scoping review protocol. JBI Evid Synth. 2020.
→ Link de acesso
› Acesso aberto
Fusar-Poli L, et al. Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies. Brain Sci. 2020 10572.
→ Link de acesso
› Acesso aberto
Ganesh A, Shareef S. Safety and Efficacy of Cannabis in Autism Spectrum Disorder. Pediatr Neurol Briefs. 2020 ;34:25.
→ Link de acesso
› Acesso aberto
Silva EAD Junior, et al. Cannabis and cannabinoid use in autism spectrum disorder: a systematic review. Trends Psychiatry Psychother. 2021.
→ Link de acesso
› Acesso aberto
Aishworiya R, et al. An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. Neurotherapeutics 2022;19(1):248-262
→ Link de acesso
› Acesso aberto
Colizzi M, et al. The Autism-Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System. Int J Environ Res Public Health 2022; 19(9):5616
→ Link de acesso
› Acesso pago
Pedrazzi JFC, Cannabidiol for the treatment of autism spectrum disorder: hope or hype? Psychopharmacology. 2022 ;239(9):2713-2734.
→ Link de acesso
› Acesso aberto
Paulus V, et al. Cannabidiol in the context of substance use disorder treatment: A systematic review. Addict Behav. 2022; 132:107360.
→ Link de acesso
› Acesso aberto
Elsaid S, Le Foll B. The complexity of pharmacology of cannabidiol (CBD) and its implications in the treatment of brain disorders. Neuropsychopharmacology.2020 ;45(1):229-230.
› Acesso aberto
Rizkallah E, et al. Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial. Pharmacol Biochem Behav 2022; 216:173376
› Acesso aberto
Mongeau-Pérusse V, et al. Cannabidiol Effect on Anxiety Symptoms and Stress Response in Individuals With Cocaine Use Disorder: Exploratory Results From a Randomized Controlled Trial. J Addict Med 2022
› Acesso aberto
Bellocchio L, Patano A, Inchingolo AD, et al. Cannabidiol for Oral Health: A New Promising Therapeutical Tool in Dentistry. Int J Mol Sci. 2023;24(11):9693. Published 2023 Jun 2. doi:10.3390/ijms24119693
› Acesso aberto
Navarrete F, et al. Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders. Front Pharmacol. 2021; 12:626010.
› Acesso aberto
Ren Y, et al. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cueinduced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci 2009; 29(47):14764–9.
› Acesso aberto
García-Gutiérrez MS, et al. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules. 2020; 10(11):1575
› Acesso aberto
Mannekote Thippaiah S, et al. Exo- and Endo-cannabinoids in Depressive and Suicidal Behaviors. Front Psychiatry. 2021; 12:636228
› Acesso aberto
Murillo-Rodríguez E, et al. The Endocannabinoid System May Modulate Sleep Disorders In Aging. Curr Neuropharmacol. 2019
› Acesso aberto
Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18-041.
› Acesso aberto
AminiLari M, et al. Medical cannabis and cannabinoids for impaired sleep: a systematic review and meta-analysis of randomized clinical trials. Sleep. 2022; 45(2):zsab234
› Acesso aberto
Kolla BP, et al. The Effects of Cannabinoids on Sleep. J Prim Care Community Health 2022; 13:21501319221081277.
› Acesso aberto
Monti JM, et al. Clinical Management of Sleep and Sleep Disorders With Cannabis and Cannabinoids: Implications to Practicing Psychiatrists. Clin Neuropharmacol 2022; 45(2):27-31
› Acesso aberto
Lavender I, et al. Cannabinoids, insomnia, and other sleep disorders. Chest 2022; 7:S0012-3692(22)00895-9
› Acesso aberto
Suraev, A., et al. Cannabidiol (CBD) and Δ 9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. BMJ Open. 2020 May 18;10(5):e034421
› Acesso aberto
Walsh JH, et al. Treating Insomnia Symptoms with Medicinal Cannabis: A Randomized, Cross-Over Trial of the Efficacy of a Cannabinoid Medicine Compared with Placebo. Sleep. 2021: zsab149.
› Acesso aberto
Andre CM, et al. Cannabis sativa: The Plant of the Thousand and One Molecules.Frontiers in plant science7, 19.
› Acesso aberto
Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012; 2(6):241−254.
› Acesso aberto
Campos AC, Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607):3364-78.
› Acesso aberto
Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis [published correction appears in Lancet Psychiatry. 2020 Jan;7(1):e3]. Lancet Psychiatry. 2019;6(12):995-1010. doi:10.1016/S2215-0366(19)30401-8
› Acesso aberto
Gottschling S, et al. Safety Considerations in Cannabinoid-Based Medicine. Int J Gen Med. 1;13:1317-1333
› Acesso aberto
Lucas CJ, et al. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018 ;84(11):2477-2482.
› Acesso aberto
Sarris J, et al. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry. 2020 16;20(1):24
› Acesso aberto
Cocetta V, et al. Cannabidiol Isolated From Cannabis sativa L. Protects Intestinal Barrier From In Vitro Inflammation and Oxidative Stress. Front Pharmacol. 2021; 12:641210
› Acesso aberto
Kienzl M, et al. Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. Clin Transl Gastroenterol. 2020 ;11(1):e00120
› Acesso aberto
Martínez V, et al. Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals? Int J Mol Sci. 2020; 21(9):3067.
› Acesso aberto
Boehnke KF, et al. Cannabidiol (CBD) in rheumatic diseases (Musculoskeletal pain). Curr Rheumatol Rep 2022; 1-9.
› Acesso aberto
Renslo B, Medical Cannabis Use Reduces Opioid Prescriptions in Patients With Osteoarthritis. Cureus. 2022; 24;14(1):e21564.
› Acesso aberto
Bryk M, Starowicz K. Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review. Pharmacol Rep. 2021; 73(3):681-699.
› Acesso aberto
Sido JM, et al. Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease. Int Rev Immunol. 2015;34(5):403-14
› Acesso aberto
Anis, Saar et al. “A single-center real-life study on the use of medical cannabis in patients with dystonia.” Frontiers in neurology vol. 14 1218300. 29 Jun. 2023, doi:10.3389/fneur.2023.1218300
› Acesso aberto
A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products
› Acesso aberto
Bains S, Mukhdomi T. Medicinal Cannabis For Treatment Of Chronic Pain. 2022 Jan 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Jan–. PMID: 34662076.
› Acesso aberto
Dykukha I, et al. Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials. Pain Med. 2021; 22(4):861-874.
› Acesso aberto
Brucki SM, et al. Cannabinoids in neurology – Brazilian Academy of Neurology. Arq Neuropsiquiatr 2015
› Acesso aberto
Guidance for the use of medicinal cannabis in the treatment of chronic non-cancer pain in Australia V1. 2017.
› Acesso aberto
Bains S, Mukhdomi T. Medicinal Cannabis For Treatment Of Chronic Pain. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
› Acesso aberto
Petzke F, et al. Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain. CNS Drugs 2022; 36(1):31-44
› Acesso aberto
Starowicz, K. & Finn, D. P. Cannabinoids and pain: Sites and mechanisms of action. Adv. Pharmacol. 80, 437–475 (2017)
› Acesso pago
Inglet S, et al. Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature. Ann Pharmacother 2020; 54(11):1109-1143
› Acesso aberto
Bapir, Lara, et al. “Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: A cohort study.” Expert Review of Neurotherapeutics 23.3 (2023)
› Acesso aberto
Nguyen, T., Li, Y., Greene, D., Stancli_, S. & Quackenbush, N. Changes in prescribed opioid dosages among patients receiving medical cannabis for chronic pain, New York state, 2017-2019. JAMA Netw. Open 6, e2254573 (2023)
› Acesso pago
Wang L, et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ 2021; 374:n1034
› Acesso aberto
Lucas et al. Cannabis significantly reduces the use of prescription opioids and improves quality of life in authorized patients: Results of a large prospective study. Pain Med. 22, 727–739 (2021).
› Acesso aberto
Dykukha I, et al. Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials. Pain Med 2021; 22(4):861-874.
› Acesso aberto
Aviram J., et al. Migraine Frequency Decrease Following Prolonged Medical Cannabis Treatment: A Cross-Sectional Study. Brain Sci. 2020 ; 10(6): 360
› Acesso aberto
Baron EP, et al. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain. 2018 May 24;19(1):37.
› Acesso aberto
Cuttler C, et al. Craft RM. Short- and Long-Term Effects of Cannabis on Headache and Migraine. J Pain. 2019
› Acesso aberto
Strzelczyk A, Schubert-Bast S. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. CNS Drugs. 2022 14.
› Acesso aberto
Mazurkiewicz-Bełdzińska M, Zawadzka M. Use of cannabidiol in the treatment of epilepsy. Neurol Neurochir Pol. 2022;56(1):14-20.
› Acesso aberto
Devinsky O, et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Wiley periodicals 2014; 55(6):791-802.
› Acesso aberto
Devinsky O, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine. Massachusetts Medical Society 2017; 376(21):2011–2020
› Acesso aberto
Farrelly AM, et al. Efficacy of Phytocannabinoids in Epilepsy Treatment: Novel Approaches and Recent Advances. Int J Environ Res Public Health. 2021; 18(8):3993
› Acesso pago
Gaston TE, et al. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. Epilepsy Behav. 2021; 117:107862
› Acesso aberto
Nicotera AG, et al. Epileptic Phenotype and Cannabidiol Efficacy in a Williams-Beuren Syndrome Patient With Atypical Deletion: A Case Report. Front Neurol. 2021; 12:659543.
› Acesso aberto
Pamplona FA, da Silva LR, Coan AC. Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Front Neurol. 2018 Sep 12;9:759
› Acesso aberto
Martin RC, et al. Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy. Epilepsy Behav 2019; 97:105-110
› Acesso aberto
Treves N, et al. Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis. Sci Rep. 2021; 11(1):23462
› Acesso aberto
Giacoppo S, Mazzon E. Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis? Neural Regen Res. 2016 ;11(12):1896-1899.
› Acesso aberto
Shoemaker JL, et al. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007 Apr;101(1):87-98.
› Acesso aberto
Filippini G, et al. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrana Database Syst Rev 2022; 5
› Acesso aberto
Furgiuele A, et al. Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review. J Neuroimmune Pharmacol. 2021; 16(2):251-269
› Acesso aberto
Jones É, Vlachou S. A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment. Molecules. 2020; 25(21):4930
› Acesso aberto
Sahinovic A, et al. Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial. Sports Med Open. 2022; 8(1):27.
› Acesso aberto
Elkington LJ, et al. Inflammation and immune function: Can antioxidants help the endurance athlete? Antioxidants in Sport Nutrition. Boca Raton (FL): CRC Press/Taylor & Francis 2015 11.
› Acesso aberto
Rojas-Valverde D. Potential role of cannabidiol on sports recovery: A narrative review. Front Physiol 2021; 12
› Acesso aberto
Fitzcharles MA, et al. Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials. Arthritis Care Res (Hoboken). 2016; 68(5):681-8.
› Acesso aberto
Lee MC, et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain. 2013; 154:124–34
› Acesso aberto
Yassin M, et al. Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study. Clin Exp Rheumatol. 2019; 37 (Suppl. 116): S13-S20.
› Acesso pago
Paduch M, Thomason AR. Potential drug interactions between cannabinoids and its derivatives and oral anticoagulants. Hosp Pharm. 2022; 57(1):188-192.
› Acesso aberto
Anderson LL, et al (2019). Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019; 60:2224–2234.
› Acesso aberto
Balachandran P, et al. Cannabidiol interactions with medications, illicit substances and alcohol: a comprehensive review. J Gen Inter Med. 2021; 36:2074-2084.
› Acesso aberto
Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer CBD use. J Clin Med 2019; 8(7):989.
› Acesso aberto
Gaston TE, et al. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017.
› Acesso aberto
Ifland K, Grotenherman F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis and Cannabinoid Res. 2017.
› Acesso aberto
Bielawiec, P., et al. . Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol. Front Endocrinol (Lausanne). 11:114. 2020 4.
› Acesso aberto
Fellous, T., et al. Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets. Biochem Pharmacol. 175: 113859.
› Acesso aberto
Rakotoarivelo V, et al. Role of the Endocannabinoid System in the Adipose Tissue with Focus on Energy Metabolism. Cells. 2021; 10(6):1279
› Acesso aberto
Cooray R, et al. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review. Mol Neurobiol. 2020;57(11):4878-4890. doi: 10.1007/s12035-020-02054-6.
› Acesso aberto
de Faria, S.M., et al. (2020) Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. J Psychopharmacol.2020; 34(2) 7:269881119895536. doi: 10.1177/0269881119895536.
› Acesso aberto
Morera−Herreras T, et al. Endocannabinoid modulation of dopaminergic motor circuits − Frontiers in Pharmacology | Neuropharmacology. June 2012 ; Volume 3 : 110 − 112.
› Acesso aberto
Patricio F, et al. Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease. Front Pharmacol. 2020; 11:595635. doi: 10.3389/fphar.2020.595635.
› Acesso aberto
Costa AC, Joaquim HPG, Pedrazzi JFC, Pain AO, Duque G, Aprahamian I. Cannabinoids in Late Life Parkinson’s Disease and Dementia: Biological Pathways and Clinical Challenges. Brain Sci. 2022;12(12):1596. Published 2022 Nov 22.
› Acesso aberto
doi:10.3390/brainsci12121596
› Acesso aberto
Millar, S. A., Stone, N. L., Bellman Z.D., Yates, A. S., England, T.J., O’Sullivan, S. E ,et al. − A systematic review of cannabidiol dosing in clinical populations. − Br J Clin Pharmacol. 2019; 85:1888−1900.
› Acesso pago
Crippa et al. Canabidiol na medicina: da pesquisa à prática clínica. 1.ed. Manole, 2023
› Acesso aberto
Martinez Naya N, Kelly J, Corna G, Golino M, Abbate A, Toldo S. Molecular and Cellular Mechanisms of Action of Cannabidiol. Molecules. 2023 Aug 9;28(16):5980. doi: 10.3390/molecules28165980. PMID: 37630232; PMCID: PMC10458707.
› Acesso aberto
Christensen C, Rose M, Cornett C, Allesø M. Decoding the Postulated Entourage Effect of Medicinal Cannabis: What It Is and What It Isn’t. Biomedicines. 2023; 11(8):2323.
› Acesso aberto
Bilbao A, Spanagel R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. 2022 Aug 19;20(1):259. doi: 10.1186/s12916-022-02459-1. PMID: 35982439; PMCID: PMC9389720
› Acesso aberto
VanDolah HJ, Bauer BA, Mauck KF. Clinicians’ Guide to Cannabidiol and Hemp Oils. Mayo Clin Proc. 2019 Sep;94(9):1840−51. Review.
› Acesso aberto
Crippa JAS, et al. Therapeutical use of the cannabinoids in psychiatry. Revista Brasileira de Psiquiatria. 2010; 32(1): 56-66.
› Acesso aberto
Davies C. e Bhattacharyya S. Cannabidiol as a potential treatment for psychosis. Ther Adv Psychopharmacol. 2019; 9: 1−16, 2019.
› Acesso pago
Leweke FM et al. Therapeutic Potential of Cannabinoids in Psychosis. Biol Psychiatry 2016; 79: 604–612.
› Acesso aberto
McGuire P., et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018; 1;175:225−231, 2018.
› Acesso aberto
Minichino A., et al. Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta−analysis. JAMA Psychiatry. June 5, 2019.
› Acesso aberto
Pedrazzi J.F.C., et al. Perfil antipsicótico do canabidiol. RevistaMedicina, Ribeirão Preto−SP, 2014; 47(2):112-119 v. 47, n. 2, p. 112−119, 2014.
› Acesso pago
Black N, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019; 6(12):995-1010.
› Acesso pago
Cooper RE, et al. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur Neuropsychopharmacol. 2017; 27(8):795-808.
› Acesso aberto
Szejko N, et al. Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome. Neurol Neurochir Pol. 2022; 56(1):28-38.
› Acesso aberto
Schwittay MA, et al. Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray. Tremor Other Hyperkinet Mov (NY). 2021; 11:33.
› Acesso aberto
Khan R, et al. The therapeutic role of Cannabidiol in mental health: a systematic review. J Cannabis Res. 2020; 2(1):2.
› Acesso aberto
Melas PA, et al. Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research. Int J Mol Sci. 2021; 22(4):1863.
› Acesso aberto
Pinto JV, et al. Cannabidiol as a Treatment for Mood Disorders: A Systematic Review. 2019; 65(4):213-227. 13:706743719895195.
› Acesso aberto
Stanciu CN, et al. Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review. Psychiatr Serv 2021; 72(4):429-436.
You cannot copy content of this page
